Skip to main content
SpringerLink
Log in
Book cover

Multisystem Diseases pp 19–47Cite as

Multiple Myeloma and Renal Function

  • Chapter

  • 32 Accesses

Part of the book series: New Clinical Applications: Nephrology ((NCNG,volume 7))

Abstract

Thomas Alexander McBean died on New Year’s Day, 1846, the cause of his death being certified as atrophy from albuminuria. Clamp1 has identified this man as being the source of the specimen of urine which Dr Thomas Watson sent to Dr Henry Bence Jones on 1st November, 1845. This urine contained a substance which Bence Jones characterized according to the understanding of chemistry in the mid-nineteenth century2 and which we now know as Bence Jones protein.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Clamp, J. R. (1967). Some aspects of the first recorded case of multiple myeloma. Lancet, 2, 1354–1356

    Article  PubMed  CAS  Google Scholar 

  2. Bence Jones, H. (1848). On a new substance occurring in the urine of a patient with mollities ossium. Phil. Trans. R. Soc, 55–62

    Google Scholar 

  3. Bence Jones, H. (1847). Papers on chemical pathology. Lecture III. Lancet, 2, 88–92

    Article  Google Scholar 

  4. Dalrymple, J. (1846). On the microscopical character of mollities ossium.Dublin J. Med. Sci., 2, 85–95

    Google Scholar 

  5. MacIntyre, W. (1850). Case of mollities et fragilitas ossium. Med. Chir. Trans., 33, 211–232

    PubMed  CAS  Google Scholar 

  6. Bayrd, E. D. and Heck, F. J. (1947). Multiple myeloma. A review of 83 proved cases. J. Am. Med. Assoc, 133, 147–157

    PubMed  CAS  Google Scholar 

  7. Salmon, S. E. and Seligmann, M. (1974). B-cell neoplasia in man. Lancet, 2, 1230–1233

    Article  PubMed  CAS  Google Scholar 

  8. Pierson, J., Darley, T., Stevenson, G. T. and Virji, M. (1980). Monoclonal immunoglobulin light chains in urine of patients with lymphomas. Br. J. Cancer, 41,681–688

    Article  PubMed  CAS  Google Scholar 

  9. Hobbs, J. R. (1967). Paraproteins — benign or malignant? Br. Med. J., 3, 699–704

    Article  PubMed  CAS  Google Scholar 

  10. Paladini, G., Sala, P.G. and Sautini, P.A. (1980). Benign Bence Jones gam-mopathy. Acta Haematol., 63, 241–246

    Article  PubMed  CAS  Google Scholar 

  11. Tubbs, R. R., Gephardt, G. N. and McMahon, J. T. (1981). Light chain nephropathy. Am. J. Med, 71, 263–269

    Article  PubMed  CAS  Google Scholar 

  12. Kyle, R. A. (1978). Monoclonal gammopathy of undetermined significance. Am. J. Med, 64, 814–826

    Article  PubMed  CAS  Google Scholar 

  13. Kyle, R. A. and Greipp, P. R. (1982). Idiopathic Bence Jones proteinuria. N. Engl. J. Med., 306, 564–607

    Article  PubMed  CAS  Google Scholar 

  14. Durie, B.G. M. and Salmon, S. E. (1977). Multiple myeloma, macro-globulinaemia and monoclonal gammopathies. In Hoffbrand, A.V., Brainm, M. L. and Hirsch, J. (eds.) Recent Advances in Haematology 2. (London: Churchill Livingstone)

    Google Scholar 

  15. Chronic Leukaemia-Myeloma Task Force (1973). National Cancer Institute. Proposed guidelines for protocol studies II: Plasma cell myeloma. Cancer Chemother. Rep., 4, 145–158

    Google Scholar 

  16. Parker, D. and Malpas, J. S. (1979). Multiple myeloma. J. R. Coll. Phys. London, 13, 146–153

    CAS  Google Scholar 

  17. Kyle, R. A. (1975). Multiple myeloma; a review of 869 cases. Mayo Clin. Proc, 50, 29–40

    PubMed  CAS  Google Scholar 

  18. Barteloni, C, Flamini, G. and Logoscino, C. (1980). IgD kappa ‘non-secretory’ multiple myeloma. Report of a case. Blood, 56, 898–901

    Google Scholar 

  19. Kapadia, S. B. (1980). Multiple myeloma: a clinicopathologic study of 62 consecutively autopsied cases. Medicine (Baltimore), 59, 380–392

    CAS  Google Scholar 

  20. Stone, M.J. and Frenkel, E.P. (1975). The clinical spectrum of light chain myeloma. Am. J. Med, 58, 601–617

    Article  PubMed  CAS  Google Scholar 

  21. Pruzanski, W. (1976). Clinical manifestation of multiple myeloma in relation to class and type of M component. Can. Med. Assoc. J., 114, 898–897

    Google Scholar 

  22. Perry, M. and Kyle, R. A. (1975). The clinical significance of Bence Jones proteinuria. Mayo Clin. Proc, 56, 234–238

    Google Scholar 

  23. Durie, B. G. M., Cole, P. W., Chen, H. S. G. et al. (1981). Synthesis and metabolism of Bence Jones protein and calculation of tumour burden in patients with Bence Jones myeloma. Br. J. Haematol., 47, 7–19

    Article  PubMed  CAS  Google Scholar 

  24. Gallango, M.C., Swinger, R. and Ramirez, M. (1980). Bence Jones myeloma with a tetramer of kappa type globulin in serum. Clin. Chem., 26, 1741–1744

    PubMed  CAS  Google Scholar 

  25. Roberts-Thompson, P. J., Venables, G.S., Onitiri, A.C. and Leavis, B. (1975). Polymeric IgA myeloma. Postgrad. Med. J., 51, 44–51

    Article  Google Scholar 

  26. Roberts-Thompson, P.J., Mason, D.Y. and MacLennan, I.C.M. (1976). Br. J. Haematol, 33, 117–130

    Article  Google Scholar 

  27. Shustik, C, Bergsagel, D. E. and Pruzanski, W. (1976). Kappa and lambda light chain disease: survival rates and clinical manifestations. Blood, 48, 41–51

    PubMed  CAS  Google Scholar 

  28. Velez, R., Beral, V. and Cuzick, J. (1982). Increasing trends of multiple myeloma mortality in England and Wales; 1950–79 are the changes real? J. Natl. Cancer Inst., 69, 387–392

    PubMed  CAS  Google Scholar 

  29. Linos, A., Kyle, R. A. and O’Fahon, L. T. (1981). Incidence and secular trend of multiple myeloma in Olmsted County, Minnesota 1965–1977. J. Natl. Cancer Inst., 66, 17–20

    PubMed  CAS  Google Scholar 

  30. Blattner, W. A. (1980). Epidemiology of multiple myeloma and related plasma cell disorders. In Potter, M. (ed.) Progress in Myeloma, pp. 1–65. (New York: Elsevier)

    Google Scholar 

  31. Egan, E. L., Grimes, H. and O’Biern, D.P. (1978). Multiple myeloma in the West of Ireland, presentation and frequency. Ir. Med. J., 71, 23–26

    PubMed  CAS  Google Scholar 

  32. Blattner, W.A., Blair, A. and Mason, T.J. (1981). Multiple myeloma in the United States 1950–1975. Cancer, 48, 2547–2554

    Article  PubMed  CAS  Google Scholar 

  33. Durie, B. G. M. and Salmon, S. E. (1975). A clinical staging system for multiple myeloma. Cancer 36, 842–854

    Article  PubMed  CAS  Google Scholar 

  34. Woodruff, R. K., Wadsworth, J., Malpas, J. S. and Tobias, J. S. (1979). Clinical staging in multiple myeloma. Br. J. Haematol., 42, 199–205

    Article  PubMed  CAS  Google Scholar 

  35. Salmon, S. E. and Wampler, S. B. (1978). Multiple myeloma. Quantitative staging and assessment of response with a programmable pocket calculator. Blood, 49, 379–389

    Google Scholar 

  36. Durie, B. G. M., Cole, P. W., Chen, H. S. G. et al. (1981). Synthesis and metabolism of Bence Jones protein and calculation of tumour burden in patients with Bence Jones myeloma. Br. J. Haematol., 47, 7–19

    Article  PubMed  CAS  Google Scholar 

  37. Medical Research Council (1973). Report on the first myelomatosis trial Part I. Analysis of presenting features of prognostic importance. Br. J. Haematol, 24, 123–139

    Article  Google Scholar 

  38. Medical Research Council (1980). Prognostic features in the third MRC myelomatosis trial. Br. J. Cancer, 42, 831

    Article  Google Scholar 

  39. Peto, R. (1971). Myeloma workshop: Urea, albumin and response rates. Br. Med. J., 1, 324

    Article  Google Scholar 

  40. Alexanian, R., Balcerzak, S., Bonner, J. D. et al. (1975). Prognostic features of multiple myeloma. Cancer, 36, 1192–1201

    Article  PubMed  CAS  Google Scholar 

  41. Matzner, Y., Benbassat, J. and Polliack, A. (1978). Prognostic factors in multiple myeloma. Acta Haematol, 60, 257–268

    Article  PubMed  CAS  Google Scholar 

  42. Colls, B. M. and Barlow, B. A. (1979). Multiple myeloma — prognosis, treatment and survival in an 8 year study. Aust. N.Z. J. Med., 9, 262–268

    Article  PubMed  CAS  Google Scholar 

  43. Durie, B.G.M., Salmon, S. E. and Moon, T. E. (1980). Pretreatment tumour mass in multiple myeloma. Blood, 55, 364–372

    PubMed  CAS  Google Scholar 

  44. Jansen, J., Huijgens, P. L. and Van der Velde, E. A. (1980). Prognosis of multiple myeloma. Neth. Med. J., 13, 246–251

    Google Scholar 

  45. Merlini, G., Waldenstrom, J.C. and Jagakar, S.D. (1980). A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients. Blood, 55, 1011–1019

    PubMed  CAS  Google Scholar 

  46. Johannsson, B. (1971). Prognostic features in mvelomatosis. Br. Med. J., 1, 327-

    Article  Google Scholar 

  47. Cornell, C. J., McIntyre, O. R., Kochwa, S. et al. (1979). Response to therapy in IgG myeloma patients excreting or light chains. CALGB experience. Blood, 54, 23–29

    PubMed  Google Scholar 

  48. Graham, R. C. and Bernier, G. M. (1975). The bone marrow in multiple myeloma. Medicine (Baltimore), 54, 225–243

    Article  Google Scholar 

  49. Latreille, J., Barlogie, B., Johnson, D. et al. (1982). Ploidy and proliferative characteristics in monoclonal gammopathies. Blood, 59, 43–51

    PubMed  CAS  Google Scholar 

  50. Gassmann, W., Pralle, H., Haferlach, T. et al. (1985). Staging systems for multiple myeloma: a comparison. Br. J. Haematol, 59, 703–711

    Article  PubMed  CAS  Google Scholar 

  51. Norfolk, D.R., Child, J.A., Cooper, E.H. et al. (1980). Serum beta2 microglobulin in myelomatosis. Potential value in stratification and monitoring. Br. J. Cancer, 42, 510–515

    Article  PubMed  CAS  Google Scholar 

  52. Morrell, A. and Riesen, W. (1980). Serum beta2 microglobulin serum creatinine and bone marrow plasma cell count in benign and malignant monoclonal gammopathy. Acta Haematol., 64, 87–93

    Article  Google Scholar 

  53. Bataille, R., Magub, M., Sany, J. et al. (1981). Beta2 microglobuline serique au cours du myelome multiple. Rev. Rheum, 48, 235–240

    CAS  Google Scholar 

  54. Bataille, R., Magub, M., Grenier, J., Donnadio, D. and Sany, J. (1981). Serum beta2 microglobulin in multiple myeloma. Relation to presenting features and clinical status. Eur. J. Cancer Clin., 18, 59–66

    Article  Google Scholar 

  55. Child, J. A., Crawford, S. M., Norfolk, D. R. et al. (1983). Evaluation of serum beta2 microglobulin as a prognostic indicator in myelomatosis. Br. J. Cancer, 47, 111–114

    Article  PubMed  CAS  Google Scholar 

  56. Cuzick, J., Cooper, E. H. and MacLennan, I. C. M. (1985). The prognostic value of serum beta2 microglobulin compared with other presentation features in myelomatosis. Br. J. Cancer, 52, 1–6

    Article  PubMed  CAS  Google Scholar 

  57. van Dobbenburgh, O. A., Rodenhuis, S., Ockhuizen, T. et al. (1985). Serum beta2 microglobulin: a real improvement in the management of multiple myeloma? Br. J. Haematol, 61, 611–620.

    Article  PubMed  Google Scholar 

  58. Colls, B. M. and Darlow, B. A. (1979). Multiple myeloma — prognosis, treatment and survival in an 8 year study. Aust. N.Z. J. Med., 9, 262–268

    Article  PubMed  CAS  Google Scholar 

  59. Alexanian, R., Fraschini, G. and Smith, L. (1984). Amyloidosis in multiple myeloma or without apparent cause. Arch. Int. Med., 144, 2158–2160

    Article  CAS  Google Scholar 

  60. Buckman, R., Cuzick, J. and Galton, D.A. G. (1982). Long-term survival in myelomatosis. Br. J. Haematol., 52, 589–599

    Article  PubMed  CAS  Google Scholar 

  61. Alexanian, R. (1985). Ten year survival in multiple myeloma. Arch. Int. Med., 145, 2073–2074

    Article  CAS  Google Scholar 

  62. Jeffries, D.J. (1985). Clinical use of acyclovir. Br. Med. J., 290, 177–178

    Article  CAS  Google Scholar 

  63. Harris, D.C.H., Ibels, L.S., Ravich, R.B.M., Isbister, J.P. and Wells, J.V. (1983). Multiple myeloma with renal failure, a case for intensive treatment. Aust. N.Z. J. Med., 13, 163–167

    Article  PubMed  CAS  Google Scholar 

  64. Coward, R. A., Mallick, N. P. and Delamore, I. W. (1983). Should patients with renal failure associated with myeloma be dialized? Br. Med. J., 287, 1575–1578

    Article  CAS  Google Scholar 

  65. Medical Research Council working party on leukaemia in adults (1984). Analysis and management of renal failure in fourth MRC myelomatosis trial. Br. Med. J., 288, 1411–1416

    Article  Google Scholar 

  66. Clyne, D. H., Pesce, A. J. and Thompson, R. E. (1979). Nephrotoxicity of Bence Jones Protein in the rat: Importance of protein isoelectric point. Kidney Int., 16, 345–352

    Article  PubMed  CAS  Google Scholar 

  67. Johns, E.A., Turner, R., Cooper, E.H. and MacLennan, I.C.M. (1986). Isoelectric points of urinary light chains in myelomatosis; analysis in relation to nephrotoxicity. J. Clin Pathol., 39, 833–837

    Article  PubMed  CAS  Google Scholar 

  68. Medical Research Council working party on leukaemia in adults (1985). Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Br. J. Cancer, 52, 153–158

    Article  Google Scholar 

  69. Bergsagel, D. E. (1985). Controversies in the treatment of plasma cell myeloma. Postgrad. Med. J., 61, 109–116

    Article  PubMed  CAS  Google Scholar 

  70. Hyrniuk, W. and Bush, H. (1986). The importance of dose intensity in chemotherapy of metastatic breast cancer. J. Clin. Oncol., 2, 1281–1288

    Google Scholar 

  71. MacLennan I. C. M. (1987). Personal communication.

    Google Scholar 

  72. Barlogie, B., Hall, R., Zander, A., Dicke, K. and Alexanian, R. (1986). High dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 67, 1298–1301

    PubMed  CAS  Google Scholar 

  73. Selby, P., McElwain, T. J., Nandi, A. A. et a.l (1987). Multiple myeloma treated with high dose intravenous melphalan. Br. J. Haematol., 66, 55–62

    PubMed  CAS  Google Scholar 

  74. Barlogie, B., Smith, L. and Alexanian, R. (1984). Effective treatment of advanced multiple myeloma refractory to alkylating agents. N. Engl. J. Med., 310, 1353–1356

    Article  PubMed  CAS  Google Scholar 

  75. Alexanian, R., Barlogie, B. and Dixon, D. (1986). High dose glucocorticoid treatment of resistant myeloma. Ann. Int. Med., 195, 8–11

    Google Scholar 

  76. Ohno, R. and Kimara, K. (1986). Treatment of multiple myeloma with recombinant interferon alpha 2a. Cancer, 57, 1685–1688

    Article  PubMed  CAS  Google Scholar 

  77. Case, D.C., Sonneborn, H.C., Paul, S.D. et al. (1986). Phase II study of r-DNA alpha 2 interferon (intron A) in patients with multiple myeloma utilising an escalating induction phase. Cancer Treat. Rep., 70, 1251–1254

    PubMed  Google Scholar 

  78. Thomas, P. J., Daban, A. and Bontoux, D. (1984). Double hemibody irradiation in chemotherapy resistant multiple myeloma. Cancer Treat. Rep., 68, 1173–1175

    PubMed  CAS  Google Scholar 

  79. Tobias, J. S., Richards, J. D., Blackman, G. M., Joannides, T., Trask, C. W. and Nathan, J. I. (1985). Hemibody irradiation in multiple myeloma. Radiother. Oncol., 3, 11–16

    Article  PubMed  CAS  Google Scholar 

  80. Hobbs, J. R. (1975). Monitoring myelomatosis. Arch. Int. Med., 135, 125–130

    Article  CAS  Google Scholar 

  81. Hobbs, J. R. (1971). Mode of escape from therapeutic control in myelomatosis. Br. Med. J., 1, 325

    Article  Google Scholar 

  82. Cohen, H.J., Bartolucci, A.A., Forman, W.B. and Silberman, H. R. (1986). Consolidation and maintenance therapy in multiple myeloma: randomised comparison of a new approach to therapy after initial response to treatment. J. Clin. Oncol., 4, 888–899

    PubMed  CAS  Google Scholar 

  83. Crawford, S. M. (1985). Hypercalcaemia, renal failure and relapse in multiple myeloma. Cancer, 55, 898–900

    Article  PubMed  CAS  Google Scholar 

  84. Bell, E.T. (1933). Renal lesions associated with multiple myeloma. Am. J. Pathol., 9, 393–419

    PubMed  CAS  Google Scholar 

  85. Foord, A. G. and Randall, L. (1935). Hyperproteinaemia, Autohaema-glutination and renal insufficiency in multiple myeloma. Am. J. Clin. Pathol., 5, 532–547

    CAS  Google Scholar 

  86. Blackman, S.S., Halsey Barker, W., Buell, M.V. and Davis, B.D. (1944). On the pathogenesis of renal failure associated with multiple myeloma. J. Clin. Invest., 23, 163–166

    Article  PubMed  CAS  Google Scholar 

  87. Rota, S., Mougenot, B., Bandoin, B. et al .(1987). Multiple myeloma and severe renal failure; a clinicopathologic study of outcome and prognosis in 34 patients. Medicine, 66, 126–137

    Article  PubMed  CAS  Google Scholar 

  88. Cohen, A. H. and Border, W.A. (1980). Myeloma kidney: An immuno-morphogenetic study of renal biopsies. Lab. Invest., 42, 248–256

    PubMed  CAS  Google Scholar 

  89. Border, W. A. and Cohen, A. H. (1980). Renal biopsy of clinically silent multiple myeloma. Ann. Int. Med., 93, 43–46

    PubMed  CAS  Google Scholar 

  90. Abrahams, C, Pirani, C.C. and Pollak, V.E. (1966). Ultrastructure of the kidney in a patient with multiple myeloma. J. Pathol Bact., 92, 220–224

    Article  CAS  Google Scholar 

  91. Sirota, J. H. and Hamerman, D. (1954). Renal function studies in an adult subject with the Fanconi syndrome. Am. J. Med., 16, 138–145

    Article  PubMed  CAS  Google Scholar 

  92. Maldonado, J. E., Velosa, J. A. and Kyle, R. A. et al. (1975). Fanconi syndrome in adults. Am J. Med., 58, 354–363

    Article  PubMed  CAS  Google Scholar 

  93. Walb, D., Wohlenberg, H., Rampelt, H.J., Schmider, H. and Thomas, L. (1980). Fanconi syndrom des Erwachsenen bei Fruhymelom mit monokloner gammopathie IgG. Typ. Kappa. Deutsche Med. Wochenschrift 195, 1355–1359

    Article  Google Scholar 

  94. Finkel, P. N., Kronentarg, K., Pesce, A. J. et al. (1973). Adult Fanconi syndrome, amyloidosis and marked kappa chain proteinuria. Nephron, 10, 1–24

    Article  PubMed  CAS  Google Scholar 

  95. Rawlings, W., Griffin, J., Duffy, T. and Humphrey, R. (1975). Fanconi syndrome with lambda light chains in urine. N. Engl. J. Med., 292, 1315

    Google Scholar 

  96. De Fronzo, R.A., Cooke, C.R., Wright, J. R. and Humphrey, R.C. (1978). Renal function in patients with multiple myeloma. Medicine (Baltimore), 57, 151–166

    Google Scholar 

  97. Smithline, N., Kassirer, J. P. and Cohen, J. J. (1976). Light chain nephropathy-renal tubular dysfunction associated with light chain proteinuria. N. Engl. J. Med., 294, 71–74

    Article  PubMed  CAS  Google Scholar 

  98. Sanchez, L. M. and Domz, C. A. (1960). Renal patterns in myeloma. Ann. Int. Med 52, 44–54

    PubMed  CAS  Google Scholar 

  99. Lazar, G. S. and Feinstein, D. I. (1981). Distal renal tubular acidosis in multiple myeloma. Arch. Int. Med., 141, 655–657

    Article  CAS  Google Scholar 

  100. Forbus, W. D., Perlzweig, W. A. and Parfentier, I. A. (1935). Bence Jones protein excretion and its effects upon the kidney. Bull. Johns Hopkins Hosp., 57, 47–69

    CAS  Google Scholar 

  101. Rees, E.G. and Waugh, W. H. (1965). Factors in the renal failure of multiple myeloma. Arch. Int. Med., 116, 400–405

    CAS  Google Scholar 

  102. Martinez-Maldonado, M., Yiam, T., Suki, W.N. and Erehogan, G. (1971). Renal complications in multiple myeloma: Pathophysiology and some aspects of clinical management. J. Chron. Dis., 24, 221–237

    Article  PubMed  CAS  Google Scholar 

  103. Schubert, G. E., Veigel, J. and Lennert, K. (1972). Structure and function of kidney in multiple myeloma. Virchow’s Arch. Pathol. Anat., 355, 135–157

    Article  CAS  Google Scholar 

  104. Clyne, D.H., Brendstrup, L., First, M.R. et al. (1974). Renal effects of intraperitoneal kappa chain injection. Lab. Invest., 2, 131–142

    Google Scholar 

  105. Beaufils, M. and Morel-Maroger, L. (1978). Pathogenesis of renal disease in monoclonal gammopathies. Current concepts. Nephron, 30, 125–131

    Article  Google Scholar 

  106. Cooper, E. H., Forbes, M. A., Crockson, R. A. and MacLennan, I. C. M. (1984). Proximal renal tubular function in myelomatosis: observations in the fourth Medical Research Council trial. J. Clin. Pathol., 37, 852–858

    Article  PubMed  CAS  Google Scholar 

  107. Randall, R. E., Williamson, W. C, Mallinson, F., Tuny, M. Y. and Still, W. J. S. (1976). Manifestations of systemic light chain deposition. Am. J. Med., 60, 293–299

    Article  PubMed  CAS  Google Scholar 

  108. Scully, R.E., Galdabini, J. and McNeely, B.U. (1981). Case records of Massachusetts General Hospital. N. Engl. J. Med., 304, 33–43

    Article  Google Scholar 

  109. Seymour, S. E., Thompson, A. J., Smith, P. S., Woodroffe, A.J. and Clarkson, A. R. (1980). Kappa light chain Glomerulosclerosis in multiple myeloma. Am. J. Pathol., 101, 557–580

    PubMed  CAS  Google Scholar 

  110. Soiling, K., Soiling, J. and Jacobsen, O. (1980). Non-secretory myeloma associated with nodular glomerulosclerosis. Acta Med. Scand., 207, 137–143

    Article  Google Scholar 

  111. Van Geelan, J. A. and Mulder, A. W. (1979). Histology and function of the kidney in marked Bence Jones proteinuria. Neth. J. Med., 22, 158–160

    Google Scholar 

  112. Nagengast, F. M., Assmann, K. J. M. and Fennis, J. F. M. (1980). Histology and function of the kidney in marked Bence Jones proteinuria. Neth. J. Med., 23, 38

    PubMed  CAS  Google Scholar 

  113. Koss, M.N., Pirani, C.L. and Osserman, E. F. (1976). Experimental Bence Jones cast nephropathy. Lab. Invest., 34, 579–591

    PubMed  CAS  Google Scholar 

  114. De Fronzo, R.A., Humphrey, R.C., Wright, J. R. and Cooke, C.R. (1975). Acute renal failure in multiple myeloma. Medicine (Baltimore), 54, 209–223

    Google Scholar 

  115. Heyburn, P. J., Child, J. A. and Peacock, M. (1981). Relative importance of renal failure and increased bone resorption in the hypercalcaemia of myelomatosis. J. Clin. Pathol., 34, 54–57

    Article  PubMed  CAS  Google Scholar 

  116. Vavatsi-Manos, O. and Preuss, H.G. (1976). The effects of high calcium concentrations on renal ammoniagenesis by the kidney slices. Nephron, 17, 474–484

    Article  PubMed  CAS  Google Scholar 

  117. Vanherweghem, J. L., Docobu, J., D’Jollander, A. and Toussaint, C. (1976). Effect of hypercalcaemia on water and sodium excretion by the isolated kidney. Pflug. Arch., 363, 75–80

    Article  CAS  Google Scholar 

  118. Nutbeam, H.M., Sinclair, L. and Oberholger, V. G. (1979). Magnesium transport deficit with hypercalcaemia. J. R. Soc. Med., 72, 932–934

    PubMed  CAS  Google Scholar 

  119. Parfitt, A.M. and Kleerekoper, M. (1980). Clinical disorders of calcium phosphorus and magnesium metabolism. In Maxwell, M. H. and Kleeman, C R. (eds.) Clinical Disorders of Fluid and Electrolyte Metabolism, 3rd Edn. (New York: McGraw Hill)

    Google Scholar 

  120. Humes, H.D. (1986). Role of calcium in pathogenesis of acute renal failure. Am. J. Physiol., 250, F579–F589

    PubMed  CAS  Google Scholar 

  121. Epstein, F. H. (1968). Calcium and the kidney. Am. J. Med., 45, 700–714

    Article  PubMed  CAS  Google Scholar 

  122. Takaichi, K., Uchida, S. and Kurokawa, K. (1986). High Ca2+ inhibit a AVP dependent cAMP production in thick ascending limbs of Henle. Am. J. Physiol., 250, F770–7706

    PubMed  CAS  Google Scholar 

  123. Teitelbaum, I. and Berl, T. (1986). Effects of calcium on vasopressin mediated cyclic adenosine monophosphate formation in cultured rat inner medullary tubule cells.J. Clin Invest., 77, 1574–1583

    Article  PubMed  CAS  Google Scholar 

  124. Benabe, J. E. and Martinez-Maldonado, M. (1978). Hypercalaemic nephropathy. Arch. Int. Med., 138, 777–779

    Article  CAS  Google Scholar 

  125. Duffy, J. L., Suzuki, Y. and Churg, J. (1971). Acute calcium nephropathy. Arch. Pathol., 91, 340–350

    PubMed  CAS  Google Scholar 

  126. Ganote, C.E., Philipsborn, D.S., Chen, E. and Carone, F.A. (1975). Acute calcium nephrotoxicity. Arch. Pathol., 99, 650–657

    PubMed  CAS  Google Scholar 

  127. Wibbell, L., Dahlberg, P.A. and Karlsson, A. (1974). Hyperparathyroidism associated with distal tubular dysfunction. Acta Med. Scand., 206, 507–510

    Article  Google Scholar 

  128. Revillard, J. P., Manuel, Y., Francois, R. and Traeger, J. (1970). Renal disease associated with tubular proteinuria. In Manuel, Y., Revillard, J. P. and Betael, H. (eds.) Protein in Normal and Pathological Urine (Basel: Karger)

    Google Scholar 

  129. Besarab, A. and Caro, J. (1978). Mechanism of hypercalcaemia in malignancy. Cancer, 41, 2276–2285

    Article  PubMed  CAS  Google Scholar 

  130. Stewart, A.F., Horst, R., Deftos, L.J. et al. (1980). Biochemical evaluation of patients with cancer associated hypercalcaemia. N. Engl. J. Med., 303, 1377–1383

    Article  PubMed  CAS  Google Scholar 

  131. Werner, S. and Low, H. (1977). Urinary excretion of CAMP and GMP in primary hyperparathyroidism with reference to clinical signs and symptoms. Horm. Metab. Res., 9, 332–336

    Article  PubMed  CAS  Google Scholar 

  132. Rude, R. K., Sharp, C F., Fredericko, R. S. et al. (1981). Urinary and nephrogenous adenosine 3′5′ monophosphate in the hypercalcaemia of malignancy. J. Clin. Endothel. Metab., 52, 765–771

    Article  CAS  Google Scholar 

  133. Raisz, L.G. (1981). What marrow does to bone. N. Engl. J. Med., 304, 1485–1486

    Article  PubMed  CAS  Google Scholar 

  134. Pootrakul, P., Hungsprenges, S. and Fucharoen, S. (1981). Relation between erythropoiesis and bone metabolism in thalassaemia. N. Engl. J. Med., 304, 1470–1473

    Article  PubMed  CAS  Google Scholar 

  135. Walter, R. M. and Greenberg, B. R. (1980). Hypercalcaemia in the accelerated phase of chronic myelogenous leukaemia. Cancer, 46, 1174–1178

    Article  PubMed  Google Scholar 

  136. Mundy, G. R., Luber, R. A., Raisz, L.G. et al. (1974). Bone resorbing activity in supernatant from lymphoid cell lines. N. Engl. J. Med., 290, 867–871

    Article  PubMed  CAS  Google Scholar 

  137. Mundy, G.R., Raisz, L.G. and Cooper, R.A. et al (1974). Evidence for the secretion of an osteoclast stimulating factor in myeloma. N. Engl. J. Med., 291, 1041–1046

    Article  PubMed  CAS  Google Scholar 

  138. Josse, R. G., Murray, T. M., Mundy, G. R. et al. (1981). Observations on the mechanisms of bone resorption induced by multiple myeloma culture fluids and partially purified osteoclast activating factor. J. Clin. Invest., 67, 1472–1481

    Article  PubMed  CAS  Google Scholar 

  139. Niel, H. B., Neely, C. L. and Palmieri, G. M. (1981). The postabsorption urinary hydrolyproline (Spot HYPRO) in patients with multiple myeloma. Cancer, 48, 783–787

    Article  Google Scholar 

  140. Mundy, G. R. (1987). The hypercalcaemia of malignancy. Kidney Int., 31, 142–155

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. S. M. Crawford
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Aberdeen, UK

    G. R. D. Catto DSc, MD, FRCP (Lond., Edin. and Glasg.) (Professor in Medicine and Therapeutics) (Professor in Medicine and Therapeutics)

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Kluwer Academic Publishers

About this chapter

Cite this chapter

Crawford, S.M. (1989). Multiple Myeloma and Renal Function. In: Catto, G.R.D. (eds) Multisystem Diseases. New Clinical Applications: Nephrology, vol 7. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-2223-5_2

Download citation

  • DOI: https://doi.org/10.1007/978-94-009-2223-5_2

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-7497-1

  • Online ISBN: 978-94-009-2223-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation